ONK Therapeutics awarded patents for CISH knockout in NK cells

By The Science Advisory Board staff writers

September 9, 2021 -- The U.S. Patent and Trademark Office has granted ONK Therapeutics patents covering the company's cytokine-inducible SH2-containing (CISH) knockout in NK cells, irrespective of the source of the NK cells.

The patents cover human cord blood-derived and human-induced pluripotent stem cell-derived cells.

Earlier this year, ONK entered an exclusive global patent license agreement with Australia's Walter and Eliza Hall Institute of Medical Research (WEHI) that provides ONK rights to CISH knockout in the field of human NK cells for the treatment of cancer, with the right to sublicense.

CIS is a protein encoded by CISH. In 2015, WEHI researchers demonstrated the role CIS plays in regulating the function of NK cells.If you like this content, please share it with a colleague!

4D microscopy reveals how malaria parasite invades red blood cells
A state-of-the-art microscopy technique has allowed Australian researchers to view parasite invasions in 4D. Using this technology, the team was able...
ONK obtains license for NK cells for cancer treatment
ONK Therapeutics announced it inked a patent license deal with Australia's Walter and Eliza Hall Institute of Medical Research for rights to CISH knockout...
ONK strengthens cell therapy manufacturing capabilities
ONK Therapeutics has entered into a license agreement with the U.S. National Institutes of Health to gain rights to make and use clinically validated...
ONK licenses 3 NK cell therapy products
ONK Therapeutics has signed three licensing agreements for natural killer (NK) cell therapy products.
Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...

Copyright © 2021 scienceboard.net


Conferences
Bio-IT World Conference and Expo
September 20-22
Boston, Massachusetts United States
BioProcess International
September 20-23
Boston, Massachusetts United States
Cell and Gene Therapy Manufacturing and Commercialization
September 20-23
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter